Intra-arterial gemcitabine and IV gemcitabine/nab-paclitaxel show similar SAEs in locally advanc...

Dr Michael Pishvaian speaks to ecancer about a study he presented at WCGIC 2203 which evaluated targeted intra-arterial gemcitabine versus continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for locally advanced pancreatic cancer.

He reports that at the first interim analysis the intra-arterial gemcitabine was found to be better the tolerated arm of the two.

Dr Pishvaian also reports that the intra-arterial gemcitabine had an overall survival of 15.7 months compared to 10 months for patients receiving continuation of IV gemcitabine plus nab-paclitaxel.